Biotechnology Value Fund
Biotechnology Value Fund is a private investment partnership based in San Francisco, focusing on fundamentally-driven public biotechnology investments. Established in 1993, the fund aims to create concentrated, long-term investments in small-cap biotechnology firms. It emphasizes rigorous due diligence and continuous monitoring of its portfolio to ensure sustainable growth. Furthermore, Biotechnology Value Fund is dedicated to collaborating with its portfolio companies, fostering partnerships that support mutual success in the biotechnology sector.
Past deals in South Dakota
SAb Biotherapeutics
Post in 2023
SAB Biotherapeutics is a clinical-stage biopharmaceutical company established in 2014, headquartered in Sioux Falls, South Dakota with additional offices in Cambridge, Massachusetts. The company specializes in developing immunotherapies using its proprietary DiversitAb platform, which employs transchromosomic cattle to produce large quantities of targeted human polyclonal antibodies without relying on human plasma or serum. SAB's pipeline includes therapies for conditions such as Type 1 diabetes (SAB-142), seasonal influenza (SAB-176), and Middle East Respiratory Syndrome Coronavirus (MERS-CoV, SAB-301).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.